Home » nnvdinrm » read more

read more

first_img News | PET-CT | August 15, 2019 United Imaging Announces First U.S. Clinical Installation of uExplorer Total-body PET/CT United Imaging announced that its uExplorer total-body positron emission tomography/computed tomography (PET/CT) system… read more Feature | Artificial Intelligence | July 19, 2019 | Michal Chorev AI Models Predict Breast Cancer With Radiologist-level Accuracy Breast cancer is the global leading cause of cancer-related deaths in women, and the most commonly diagnosed cancer… read more Related Content News | Mammography Reporting Software | July 26, 2019 Ikonopedia Releases Automated Combined Reporting Package at AHRA Ikonopedia showcased its recently released Automated Combined Reporting package and its entire suite of structured… read more Technology | Breast Biopsy Systems | July 24, 2019 Fujifilm Releases Tomosynthesis Biopsy Option for Aspire Cristalle Mammography System Fujifilm Medical Systems U.S.A. Inc. recently expanded its breast imaging solutions with the launch of its… read more News | Radiopharmaceuticals and Tracers | July 26, 2019 NorthStar Medical Radioisotopes Awarded $30 Million by U.S. Department of Energy NorthStar Medical Radioisotopes LLC has been awarded $15 million in a cooperative agreement with the U.S. Department of… read more News | Breast Imaging | August 02, 2019 Volpara to Distribute Screenpoint Medical’s Transpara AI Solution Volpara Solutions and ScreenPoint Medical BV signed an agreement under which Volpara will sell ScreenPoint’s Transpara… read more IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017, and who had health records for at least one year prior to the mammogram. The algorithm was trained on 9,611 mammograms. Image courtesy of Radiology. News | Mammography | August 14, 2019 Imago Systems Announces Collaboration With Mayo Clinic for Breast Imaging Image visualization company Imago Systems announced it has signed a know-how license with Mayo Clinic. The multi-year… read more center_img Technology | Artificial Intelligence | July 18, 2019 Paragon Biosciences Launches Qlarity Imaging to Advance FDA-cleared AI Breast Cancer Diagnosis System Paragon Biosciences LLC announced the launch of its seventh portfolio company, Qlarity Imaging LLC, which was founded… read more Technology | Mammography Reporting Software | July 25, 2019 Hologic Partners With MagView to Develop Unifi EQUIP Solution Hologic announced a partnership with mammography information solutions provider MagView to develop Unifi EQUIP, an… read more June 15, 2012 — Several groundbreaking studies on the Naviscan PET scanner, the breast application for which is positron emission mammography (PEM), were presented this week at the annual meeting of the Society of Nuclear Medicine (SNM) in Miami, Fla. Researchers from the Johns Hopkins University, Thomas Jefferson University, Boston University and University of Washington presented abstracts focusing on use of novel radiotracers, new clinical applications as well as low-dose imaging with PEM. Mathew Thakur, M.D., from Thomas Jefferson University presented results of an ongoing head-to-head comparison of 18F-FDG with a novel low-dose radiotracer Cu-64-TP3805 (NuView Life Sciences, Park City, UT) demonstrating concordance. This is significant since the dose from Cu-64 is similar to one mammogram and does not require fasting indicating a potential for PEM to be used in a screening capacity. Richard Wahl, M.D. of Johns Hopkins University presented results on feasibility of using the technology for metabolic assessment and evaluation of treatment response for patients with osteoarthritis. Gustavo Mercier, M.D. from Boston University and Lawrence MacDonald from University of Washington shared clinical and research validations of performing PEM imaging using 50 percent less radiation. PEM imaging shows the location as well as the metabolic phase of a lesion. This information is critical in determining whether a lesion is malignant and influences the course of treatment by providing an ability to distinguish between benign and malignant lesions, what researchers term “specificity.” Recent studies have demonstrated that PEM has similar sensitivity and higher specificity than breast MRI. The scanner is the only U.S. Food and Drug Administration-cleared, CE-certified 3D molecular breast imaging (MBI), device on the market with biopsy-guidance. For more information: www.naviscan.com  FacebookTwitterLinkedInPrint分享 Qlarity Imaging’s software is used to assist radiologists in the assessment and characterization of breast lesions. Imaging features are synthesized by an artificial intelligence algorithm into a single value, the QI score, which is analyzed relative to a database of reference abnormalities with known ground truth. Image courtesy of Business Wire. News | June 15, 2012 Naviscan PEM Research Presented At SNM 2012 Studies focused on novel radiotracers, new applications and clinical validation of low-dose positron emission mammography Image courtesy of Imago Systems News | Radiopharmaceuticals and Tracers | August 02, 2019 ASRT Supports Radiopharmaceutical Reimbursement Bill The American Society of Radiologic Technologists (ASRT) announced its support for House Resolution (HR) 3772, a measure… read more last_img

Leave a Reply

Your email address will not be published. Required fields are marked *

*
*